Epithelial–mesenchymal transition (EMT) is a reversible and dynamic biological process in
which epithelial cells acquire mesenchymal characteristics including enhanced stemness …

Over the past decade, the capacity of cancer cells to oscillate between epithelial and
mesenchymal phenotypes, termed epithelial plasticity (EP), has been demonstrated to play …

Historically, androgen-deprivation therapy (ADT) was the only primary treatment for
metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate …

Docetaxel-based chemotherapy, as the first-line treatment for metastatic castration-resistant
prostate cancer (mCRPC), has succeeded in helping quite a number of patients to improve …

Abstract NAD [P] H: quinone oxidoreductase 1 (NQO1) regulates cell fate decisions in
response to stress. Oxidative stress supports cancer maintenance and progression …

Purpose Docetaxel resistance is a significant obstacle in the treatment of prostate cancer
(PCa), resulting in unfavorable patient prognoses. Intratumoral heterogeneity, often …

The prostatic tumor cells plasticity is involved in resistance to hormone-therapy, allowing
these cells to survive despite androgen receptor inhibition. However, its role in taxanes …

Background To investigate the roles of androgen receptor (AR) in epithelial-mesenchymal
transition (EMT) in human prostate cancer stem progenitor (S/P) cells isolated from LNCaP …

Chemotherapy is an important treatment option for advanced prostate cancer, especially for
metastatic prostate cancer (PCa). Resistance to first-line chemotherapeutic drugs such as …

TMPRSS2‐ERG expression in blood has been correlated with low docetaxel benefit in
metastatic castration‐resistant prostate cancer (mCRPC). This multicenter study aimed to …